Page last updated: 2024-10-25

cilostamide and Obesity

cilostamide has been researched along with Obesity in 3 studies

cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"Obesity is associated with the development of leptin resistance."7.72Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. ( Bhatt, BA; Dedousis, N; Huang, W; O'Doherty, RM, 2004)
"Obesity is associated with the development of leptin resistance."3.72Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity. ( Bhatt, BA; Dedousis, N; Huang, W; O'Doherty, RM, 2004)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Huang, W1
Dedousis, N1
Bhatt, BA1
O'Doherty, RM1
Geoffroy, V1
Fouque, F1
Lugnier, C1
Desbuquois, B1
Benelli, C1
Netherton, SJ1
Jimmo, SL1
Palmer, D1
Tilley, DG1
Dunkerley, HA1
Raymond, DR1
Russell, JC1
Absher, PM1
Sage, EH1
Vernon, RB1
Maurice, DH1

Other Studies

3 other studies available for cilostamide and Obesity

ArticleYear
Impaired activation of phosphatidylinositol 3-kinase by leptin is a novel mechanism of hepatic leptin resistance in diet-induced obesity.
    The Journal of biological chemistry, 2004, May-21, Volume: 279, Issue:21

    Topics: Androstadienes; Animals; Chromones; Diet; Dose-Response Relationship, Drug; Enzyme Inhibitors; Insul

2004
Characterization of an in vivo hormonally regulated phosphodiesterase 3 (PDE3) associated with a liver Golgi-endosomal fraction.
    Archives of biochemistry and biophysics, 2001, Mar-01, Volume: 387, Issue:1

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type

2001
Altered phosphodiesterase 3-mediated cAMP hydrolysis contributes to a hypermotile phenotype in obese JCR:LA-cp rat aortic vascular smooth muscle cells: implications for diabetes-associated cardiovascular disease.
    Diabetes, 2002, Volume: 51, Issue:4

    Topics: 1-Methyl-3-isobutylxanthine; 3',5'-Cyclic-AMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imi

2002